BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Monday, May 20, 2024
Breaking News: Try BioWorld for free for two weeks
See today's BioWorld Science
Home
» Dtx Pharma’s siRNA therapeutic Dtx-1252 awarded US orphan drug designation for CMT1A
To read the full story,
subscribe
or
sign in
.
Neurology/Psychiatric
Dtx Pharma’s siRNA therapeutic Dtx-1252 awarded US orphan drug designation for CMT1A
June 8, 2023
No Comments
Dtx Pharma Inc.’s Dtx-1252, an investigational small interfering RNA (siRNA) therapeutic, has been awarded U.S. orphan drug designation for the treatment of Charcot-Marie-Tooth disease type 1A (CMT1A).
BioWorld Science
Neurology/psychiatric
FDA
Orphan drug